Chapter 1. Research Background
1.1. Research Objectives
1.2. Market Definition
1.3. Research Scope
1.3.1. Market Segmentation by Mode of Treatment
1.3.2. Market Segmentation by Geography
1.3.3. Analysis Period
1.3.4. Market Data Reporting Unit
1.4. Key Stakeholders
Chapter 2. Research Methodology
2.1. Secondary Research
2.2. Primary Research
2.2.1. Breakdown of Primary Research Respondents
2.2.1.1. By region
2.2.1.2. By industry participants
2.2.1.3. By company type
2.3. Market Size Estimation
2.4. Market Breakdown and Data Triangulation
2.5. Assumptions for the Study
Chapter 3. Executive Summary
Chapter 4. Introduction
4.1. Market Segmentation
4.1.1. Overview by mode of Treatment
4.1.1.1. Disease Modifying Therapies
4.1.1.1.1. Angiotensin-Converting Enzyme Inhibitors
4.1.1.1.2. Angiotensin Receptor Blockers
4.1.1.1.3. Diuretics
4.1.1.1.4. Calcium Channel Blockers
4.1.1.1.5. Renin Inhibitors
4.1.1.1.6. Connective Tissue Growth Factor Inhibitors
4.1.1.1.7. Antioxidant Inflammation Modulator
4.1.1.1.8. Monocyte Chemoattractant Proteins Inhibitor
4.1.1.1.9. Endothelin-A Receptor Antagonist
4.1.1.1.10. G Protein-Coupled Receptors
4.1.1.2. Others
4.2. Value Chain Analysis
4.3. Market Dynamics
4.3.1. Trends
4.3.2. Drivers
4.3.2.1. Impact analysis of drivers on market forecast
4.3.3. Restraints
4.3.3.1. Impact analysis of restraints on market forecast
4.3.4. Opportunities
4.4. Porter’s Five Forces Analysis
Chapter 5. Market Size and Forecast by mode of Treatment
5.1. Disease Modifying Therapies
5.1.1. Angiotensin-Converting Enzyme Inhibitors
5.1.2. Angiotensin Receptor Blockers
5.1.3. Diuretics
5.1.4. Calcium Channel Blockers
5.1.5. Renin Inhibitors
5.1.6. Connective Tissue Growth Factor Inhibitors
5.1.7. Antioxidant Inflammation Modulator
5.1.8. Monocyte Chemoattractant Proteins Inhibitor
5.1.9. Endothelin-A Receptor Antagonist
5.1.10. G Protein-Coupled Receptors
5.2. Others
Chapter 6. Market Size and Forecast by Geography
6.1. North America Diabetic Nephropathy Market
6.1.1. By Mode of Treatment
6.1.2. By Country-The U.S and Canada
6.2. Europe Diabetic Nephropathy Market
6.2.1. By Mode of Treatment
6.2.2. By Country –Germany, France, U.K and Rest of Europe
6.3. Asia-Pacific Diabetic Nephropathy Market
6.3.1. By Mode of Treatment
6.3.2. By Country -China, Japan, India and Rest of Asia-Pacific
6.4. Latin America Diabetic Nephropathy Market
6.4.1. By Mode of Treatment
6.5. Middle East & Africa Diabetic Nephropathy Market
6.5.1. By Mode of Treatment
Chapter 7. Competitive Landscape
7.1. Competitive Analysis of Key Players
7.2. Global Strategic Developments
Chapter 8. Company Profiles
8.1. Novartis AG
8.1.1. Business Overview
8.1.2. Product and Service Offerings
8.1.3. Key Financial Summary
8.1.4. Strategic Growth Plan
8.2. Merck & Co., Inc.
8.2.1. Business Overview
8.2.2. Product and Service Offerings
8.2.3. Key Financial Summary
8.2.4. Strategic Growth Plan
8.3. Pfizer, Inc
8.3.1. Business Overview
8.3.2. Product and Service Offerings
8.3.3. Key Financial Summary
8.3.4. Strategic Growth Plan
8.4. Abbott Laboratories
8.4.1. Business Overview
8.4.2. Product and Service Offerings
8.4.3. Key Financial Summary
8.4.4. Strategic Growth Plan
8.5. Sanofi
8.5.1. Business Overview
8.5.2. Product and Service Offerings
8.5.3. Key Financial Summary
8.5.4. Strategic Growth Plan
8.6. Eli Lilly and Company
8.6.1. Business Overview
8.6.2. Product and Service Offerings
8.6.3. Key Financial Summary
8.6.4. Strategic Growth Plan
8.7. Bayer AG
8.7.1. Business Overview
8.7.2. Product and Service Offerings
8.7.3. Key Financial Summary
8.7.4. Strategic Growth Plan
8.8. Mitsubishi Tanabe Pharma Corporation
8.8.1. Business Overview
8.8.2. Product and Service Offerings
8.8.3. Key Financial Summary
8.8.4. Strategic Growth Plan
8.9. Reata Pharmaceuticals, Inc.
8.9.1. Business Overview
8.9.2. Product and Service Offerings
8.9.3. Key Financial Summary
8.9.4. Strategic Growth Plan
8.10. AbbVie Inc.
8.10.1. Business Overview
8.10.2. Product and Service Offerings
8.10.3. Key Financial Summary
8.10.4. Strategic Growth Plan
*Note: Key financial summary and strategic growth plan will be provided on best effort basis and is subject to availability during primary and secondary research.
Chapter 9. Appendix
9.1. Abbreviations
